Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy

Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bermudez, Maria V, Papa, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900909/
https://www.ncbi.nlm.nih.gov/pubmed/31816083
http://dx.doi.org/10.1093/rheumatology/kez402
_version_ 1783477421347962880
author Bermudez, Maria V
Papa, Sophie
author_facet Bermudez, Maria V
Papa, Sophie
author_sort Bermudez, Maria V
collection PubMed
description Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set the scene covering the history of CPI therapy to date and outlining the likely future developments.
format Online
Article
Text
id pubmed-6900909
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-69009092019-12-16 Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy Bermudez, Maria V Papa, Sophie Rheumatology (Oxford) Supplement Articles Cancer immune therapy with checkpoint inhibitors (CPIs) has changed the landscape of treatment for a growing number of indications. These drugs are associated with a specific mechanism of action that has profound implications for both immunology and inflammatory disease. This article looks to set the scene covering the history of CPI therapy to date and outlining the likely future developments. Oxford University Press 2019-12 2019-12-09 /pmc/articles/PMC6900909/ /pubmed/31816083 http://dx.doi.org/10.1093/rheumatology/kez402 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Articles
Bermudez, Maria V
Papa, Sophie
Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title_full Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title_fullStr Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title_full_unstemmed Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title_short Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
title_sort setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900909/
https://www.ncbi.nlm.nih.gov/pubmed/31816083
http://dx.doi.org/10.1093/rheumatology/kez402
work_keys_str_mv AT bermudezmariav settingthesceneafutureepidemicofimmunerelatedadverseeventsinassociationwithcheckpointinhibitortherapy
AT papasophie settingthesceneafutureepidemicofimmunerelatedadverseeventsinassociationwithcheckpointinhibitortherapy

Ejemplares similares